What is Altimmune's investing cash flow?

Altimmune (ALT) reported investing cash flow of -$3.69M in Q1 2026.

How has Altimmune's investing cash flow changed year-over-year?

Altimmune's investing cash flow increased by 27.7% year-over-year, from -$5.1M to -$3.69M.

What is the long-term trend for Altimmune's investing cash flow?

Over 2 years (2021 to 2025), Altimmune's investing cash flow has grown at a 23.0% compound annual growth rate (CAGR), from $87.52M to -$132.47M.

What does investing cash flow mean?

Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Altimmune ALT Investing Cash Flow

Investing Cash Flow at other companies

Eli LillyLLY

-$3.92B-16.8%

Merck & Co.MRK

-$10.21B-587%

Madrigal Pharmaceuticals, Inc.MDGL

$192.19M+17.3%

Viking TherapeuticsVKTX

$54.19M-14.3%

Wave Life SciencesWVE

-$438K-165%

Delcath SystemsDCTH

-$571K+97.7%

Other financials

Income statement

See full

Revenue$26.0K+420%

Operating income-$24.2M-11.1%

Net income-$22.6M-15.3%

EPS (diluted)-$0.18+30.8%

Balance sheet

See full

Cash & equivalents$97.6M+98.7%

Total debt$34.8M+14,092%

Total equity$284.0M+99.8%

Total assets$335.6M+113%

Cash flow

See full

Operating cash flow-$20.9M-24.4%

CapEx$21.0K—

Free cash flow-$21.0M—

Valuation

See full

Market cap$558.14M-2.1%

Enterprise value$495.27M-5.0%

P/S13,613.2×-24,380×

Profitability

See full

Operating margin-230,461%-82,087pp

Net margin-214,861%-76,057pp

FCF margin-17,806.8%-110,030pp

Returns & leverage

See full

Return on equity-42.7%-8.7pp

Debt / equity0.1×+0.1×

Current ratio29.6×+13.7×

Where this comes from

Reported directly by Altimmune in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Altimmune's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Altimmune's investing cash flow?: Altimmune (ALT) reported investing cash flow of -$3.69M in Q1 2026.
How has Altimmune's investing cash flow changed year-over-year?: Altimmune's investing cash flow increased by 27.7% year-over-year, from -$5.1M to -$3.69M.
What is the long-term trend for Altimmune's investing cash flow?: Over 2 years (2021 to 2025), Altimmune's investing cash flow has grown at a 23.0% compound annual growth rate (CAGR), from $87.52M to -$132.47M.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.